Growth Metrics

Moderna (MRNA) Share-based Compensation (2018 - 2026)

Moderna (MRNA) has disclosed Share-based Compensation for 9 consecutive years, with $104.0 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation fell 9.57% year-over-year to $104.0 million; the TTM value through Mar 2026 reached $472.0 million, up 6.55%, while the annual FY2025 figure was $483.0 million, 12.59% up from the prior year.
  • Share-based Compensation hit $104.0 million in Q1 2026 for Moderna, down from $113.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $130.0 million in Q2 2025 and bottomed at $44.0 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $91.0 million, with a median of $101.0 million recorded in 2024.
  • Year-over-year, Share-based Compensation surged 75.0% in 2022 and then decreased 9.57% in 2026.
  • Moderna's Share-based Compensation stood at $62.0 million in 2022, then increased by 27.42% to $79.0 million in 2023, then soared by 31.65% to $104.0 million in 2024, then rose by 8.65% to $113.0 million in 2025, then fell by 7.96% to $104.0 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $104.0 million, $113.0 million, and $125.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.